
|Articles|September 1, 2004
Distinguishing BPH from PCa: Outlook for a test is bright
Hopefully critical analysis of the MTOPS samples will yield useful biomarkers within the next couple of years.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
5






